Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • September 2017 •
  • 137 pages •
  • Report ID: 5190775 •
  • Format: PDF
Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

Summary
Diabetes mellitus (DM) is a generalized term used to define multiple diseases with different etiologies that are characterized by chronic hyperglycemia (high blood glucose levels) resulting from insufficient synthesis, secretion or signaling of insulin - a hormone produced by the pancreas. The main role of insulin is to facilitate the absorption of glucose into skeletal muscle and fat cells following food digestion, which provides these cells with a source of energy for metabolism, and also reduces the concentration of glucose in the blood. Insulin signaling also has important roles in many processes including growth, development and controlling inflammation.

The DM market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter 2 (SGLT-2) inhibitors. Increased market diversification is expected to continue throughout the forecast period due to patent expiries for major insulin products and increased uptake of non-insulin drugs.

Incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for more than 90% of all DM cases, is growing rapidly on a global scale. The US is expected to experience the greatest rise in T2DM prevalence, and incidence rates are also expected to increase to about 4% by 2023. Several factors are driving the increase of T2DM, with aging population and the prevalence of highly calorific diets being some of the key drivers.

In 2016, the top five products, all of which are insulin products, commanded almost half of the market by sales. By 2023, the top 10 products are expected to occupy more than 40% of the market share, many of which will be non-insulin products.

Competition will intensify over the forecast period as more companies enter the DM market space. However, Novo Nordisk, which is currently the leading player in terms of market share, is expected to maintain its position throughout the forecast period. Despite declining revenues for high-grossing products such as Levemir (insulin detemir), more recent market additions such as Tresiba (insulin degludec), as well as the upcoming pipeline products such as semaglutide and oral semaglutide are expected to more than compensate.

The report “Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes” comprehensively reviews the strategies of key players in the DM market, and provides market share forecasts. Pipeline and marketed products are analyzed in detail, along with the impact that products expected to come to market between 2016 and 2023 will have on existing established products. Licensing and co-marketing deals in DM are analyzed by region and value.

Companies mentioned in this report: Sanofi, Novo Nordisk, Eli Lilly, Merck and Co, Novartis, Boehringer Ingelheim, Johnson and Johnson, AstraZeneca.

Scope
- Global revenue from the DM market between 2016 and 2023
- Novel compounds and new drugs achieving blockbuster status by 2023
- Analysis of market share changes for leading compounds by 2023
- Analysis of leading companies by market share
- Analysis of deals conducted during the 2006-2017 period

Reasons to buy
- Understand the current treatment landscape, with profile assessments of key marketed products and a focus on historical and forecast sales patterns.
- Gain insight into a highly diversifying market for DM products, and the factors behind the significant changes projected in market share between key compounds.
- Analyze the DM pipeline through a comprehensive review of products, segmented by stage of development, molecule type and molecular target - as well as detailed profile assessments and multi-scenario revenue projections for the most promising late-stage pipeline candidates.
- Consider market opportunities and potential risks associated with attempting to bring pipeline products to market by examining trends in clinical trial size, duration and failure rate by stage of development, key indication, molecule type and molecular target.
- Predict growth in market size, with multi-scenario forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify the leading companies in the DM market and understand the factors that will influence growth and market share with profile assessments of key companies, including multi-scenario revenue projections.
- Identify commercial opportunities in the DM deals landscape by analyzing trends in licensing and co-development deals.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.